Previous Close | 17.66 |
1-Year Change | -19.76% |
6-Months Change | 15.8% |
3-Months Change | 15.5% |
Moving Avg (50d) | 15.449 |
Moving Avg (200d) | 17.702 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.94B |
Beta (3-Years) | 1.04 |
Revenue Growth (ttm) | 47.06% |
Net Profit Margin (ttm) | 13.83% |
Return On Assets (ttm) | 13.15% |
EPS (ttm) | 280.06 |
PE Ratio (ttm) | 0.06 |
Dividend Yield | % |
Asset Description: | ACADIA Pharmaceuticals Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
16.595 | 17.084 | 17.409 | 17.897 | 18.711 | 19.524 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California. Wikipedia